1. Congdon NG et al. Central corneal thickness and corneal hysteresis associated with glaucoma damage. Am J Ophthalmol. 2006, Vols. 141: 868-875.

2. Leske MC, Heijl A, Hussein M, Bengsston B, Hyman L, Konaroff E for the Early Manifest Glaucoma Trial Group. Factors for Glaucoma Progression and the effect of treatment. The Early Manifest Glaucoma Trial. Arch Ophthalmol. 2003, Vols. 121: 48-56.

3. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham E e Johnson C, Keltner J, Miller PJ, Parrish RK, Wilson RM, Kass MA, for the Ocular Hypertensive Treatment Study. The Ocular Hypertensive Treatment Study. Baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002, Vols. 120: 714-720.

4. PA, Chandler. Long-term results of glaucoma therapy. Am J Ophthalmol. 1960, Vols. 49:221-246.

5. The Ocular Hypertension Treatment Study. A randomized trial determines that topical hypotensive medication delays or prevents the onset of POAG. Arch Ophthalmol. 2002, Vols. 120:701-703, pp. 120: 701-703.

6. Brandt JD, Beiser JA, Kass MA, Gordon MO for The Ocular Hypertensive Treatment Study (OHTS) Group. Central corneal thickness in the Ocular Hypertensive Treatment Study (OHTS). Ophthalmology. 2001, Vols. 108: 1779-1788.

7. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M, for the Early manifest Glaucoma Study Group. Reduction of Intraocular Pressure and Glaucoma Progression. Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002, Vols. 120: 1268-1279.

8. Leske MC, Heijl A, Hyman L et al. Predictors of long-term progression in the Early Manifest Glaucoma Trial. Ophthalmology. 2007, Vols. 114(11): 1965-1972.

9. The AGIS Investigators . Tha Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000, Vols. 130: 429-440.

10.Collaborative normal tension glaucoma study group. Comparison of glaucomatous progression between untreated patients with normal tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998, Vols. 126: 487-497.

11. Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz PA, Wren PA, Mills RP and the CIGTS Study Group. Interim Clinical Outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medication or surgery. Ophthalmology . 2001, Vols. 108: 1943-1953.

12.  Wahl J. Results of the Collaborative Initial Glaucoma Treatment Study. Ophthalmologe. 2005, Vols. Mar; 102(3): 222-226.

13. Janz NK, Wren PA, Guire KE, Musch DC, Gillespie BW, Lichter PR,Collaborative Initial Glaucoma Treatment Study. . Fear of blindness in Initial Glaucoma Treatment Study: patterns and correlates over time. Ophthalmology. 2007, Vols. Dec; 114(12): 1694-1700.

14. Boel Bengtsson, M. Cristina Leske, Leslie Hyman,Anders Heijl, Early Manifest Glaucoma Trial Group. Fluctuation of Intraocular Pressure and Glaucoma Progression in the Early Manifest Glaucoma Trial. Ophthalmology . 2007, Vols. 114: 205–209.

15. Drance S, Anderson DR, Schulzer M for the Collaborative Normal tension Study Group. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol. 2001, Vols. 131:699 –708.

16. Ghergel D, Orgul S, Gugleta K, Gekkieva M, Flammer J. Relationship between ocular perfusion pressure and retrobulbar blood flow in patients with glaucoma with progressive damage. Am J Ophthalmol . 2000, Vols. 130: 597-605.

17. Satilmis M, Orgul S, Doubler B, Flammer J. Rate of progression in Glaucoma correlates with retrobulbar circulation and intraocular pressure. Am J Ophthalmol. 2003, Vols. 135:597-605.

4ª Edição - Maio 2017